drugset / Trial / NCT00355199

Comparison of HD Chemotherapy Followed by Auto-transplant and R-CHOP in High Risk Patients With DLBCL.

NCT00355199 ↗

Phase 3 Completed 246 enrolled Gruppo Italiano Terapie Innovative nei Linfomi
RandomizedParallel-groupOpen-labelTreatment

Summary

Multicentric randomized phase III study comparing high doses of chemotherapy with Rituximab followed by auto-transplant HPC versus CHOP plus Rituximab as first line therapy in high risk patients with DLBCL Non-Hodgkin's lymphomas.

Timeline

Start
2005-05
Primary completion
2013-03
Completion
2013-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Cisplatin Other / unclassified — —
Subject Cyclophosphamide Other / unclassified — —
Subject Cytarabine Small molecule — —
Comparator Doxorubicin Other / unclassified — —
Subject Etoposide Small molecule — —
Subject Methotrexate Small molecule — —
Comparator Prednisone Other / unclassified — —
Comparator Vincristine Small molecule — —
Background Rituximab Monoclonal antibody — —